Joe Salas
Overview
Explore the profile of Joe Salas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Flier A, Hong V, Liu Z, Piepenhagen P, Ulinski G, Dumont J, et al.
Blood Coagul Fibrinolysis
. 2023 Aug;
34(6):353-363.
PMID: 37577860
Extended half-life recombinant FIX (rFIX) molecules have been generated to reduce the dosing burden and increase the protection of patients with hemophilia B. Clinical pharmacology studies with recombinant factor IX...
2.
Demers M, Aleman M, Kistanova E, Peters R, Salas J, Seth Chhabra E
J Thromb Haemost
. 2022 Apr;
20(7):1674-1683.
PMID: 35466511
Background: Factor VIII (FVIII) binding to endogenous von Willebrand factor (VWF) has constrained half-life extension of recombinant FVIII (rFVIII) products for hemophilia A. Efanesoctocog alfa (rFVIIIFc-VWF-XTEN; BIVV001) is a novel...
3.
Seth Chhabra E, Liu T, Kulman J, Patarroyo-White S, Yang B, Lu Q, et al.
Blood
. 2020 Feb;
135(17):1484-1496.
PMID: 32078672
Factor VIII (FVIII) replacement products enable comprehensive care in hemophilia A. Treatment goals in severe hemophilia A are expanding beyond low annualized bleed rates to include long-term outcomes associated with...
4.
Leksa N, Aleman M, Goodman A, Rabinovich D, Peters R, Salas J
J Thromb Haemost
. 2019 Mar;
17(7):1044-1052.
PMID: 30887655
Background: Activated factor VIII (FVIIIa) mimetic bsAbs aim to enable prophylactic treatment of hemophilia A patients with and without inhibitors. With different mechanisms of action, benchmarking their activity against FVIII...
5.
Aleman M, Leksa N, Peters R, Salas J
Expert Rev Mol Diagn
. 2018 Dec;
19(1):1-3.
PMID: 30513018
No abstract available.
6.
Kis-Toth K, Rajani G, Simpson A, Henry K, Dumont J, Peters R, et al.
Blood Adv
. 2018 Nov;
2(21):2904-2916.
PMID: 30396910
The main complication of replacement therapy with factor in hemophilia A (HemA) is the formation of inhibitors (neutralizing anti-factor VIII [FVIII] antibodies) in ∼30% of severe HemA patients. Because these...
7.
Salas J, Liu T, Lu Q, Kulman J, Ashworth T, Kistanova E, et al.
Thromb Res
. 2015 Feb;
135(5):970-6.
PMID: 25721936
Recombinant Factor VIIa (rFVIIa) is utilized for on-demand treatment of bleeding episodes in hemophilia patients with neutralizing antibodies (inhibitors) against Factor VIII or Factor IX, but a short half-life in...